Open in interactive viewer → charts, metric popovers & call review

Milestone Scientific Moves Breakeven Into Q4 — And Hands the Fourth Quarter a Revenue Number It Hasn't Printed in Years

A $26 million microcap pulled profitability forward by two quarters, but the recurring-revenue pivot that supposedly gets it there is still six months from mattering — and the Ambassador program, Japan, and the VA order update all quietly vanished from the script.
MLSS · Earnings Call · 2026-11-13

A promise pulled forward

For as long as Eric Hines has been running Milestone Scientific, the guidance has been some form of cash flow breakeven by 2027. In April he put a number on his own disappointment threshold: “if we can't get to breakeven next year, I'll be disappointed.” — Eric Hines, Chief Executive Officer · 2026-04-01 Seven months later, breakeven has a date and it is five weeks away. “our team identified approximately $400,000 in additional annual savings, which we believe supports our expectation to approach or achieve profitability in the fourth quarter of 2026” — Eric Hines, CEO · 2026-11-13 — and then, unusually, he said it a second time, unprompted. Double-stating a guidance line in prepared remarks is what a CEO does when he wants the tape to hear it. The mechanics behind the pull-forward are real enough. Operating expense fell 15.3% to $2.4 million, gross margin rose 280 basis points to 72.3%, and the net loss narrowed to $748,000 from $1.2 million. More tellingly, the actual cash drain is far smaller than the income statement implies: free cash flow (excluding stock comp) ran at roughly negative $158,000 for the quarter, an 88% year-over-year improvement. Breakeven on a cash basis from here is a plausible accounting claim. Breakeven on revenue is a different matter.

This is a new chapter for the company. We are now at a place where the operating leverage for the company throws any incremental revenue to the bottom line.

Eric Hines, CEO · 2026-11-13

The arithmetic does not fit the recent past

Total revenue was $2.2 million, down 5.9% year over year, described as "a modest sequential decline" after two large international orders landed in the second quarter. Against that, the company reaffirmed a full-year range of $9.8 million–$10.2 million, framed as double-digit growth. Run the numbers and the implied fourth quarter is somewhere above $3 million — roughly 40% above the quarter just reported, and higher than any quarter in the last six years except one. The CEO's own breakeven math is stated plainly: “quarterly revenue of approximately $2.6 million-$2.7 million puts us near the threshold where incremental revenue begins to flow meaningfully to the bottom line.” — Eric Hines, CEO · 2026-11-13 Guidance therefore doesn't just require the threshold — it requires clearing it comfortably. That's a hard ask on a revenue line whose multi-year shape is down roughly 35% over the last two years. It also contradicts the company's own prior framing of seasonality. Asked about a strong fourth quarter a year ago, Hines was emphatic about steadiness: “It's very steady... we expect a similar quarter in Q4. So no real huge inflection in Q4. It's a pretty steady business.” — Eric Hines, Chief Executive Officer · 2025-11-14 Today the fourth quarter must be the inflection. And the near-term forecasting record is imperfect: on the August call the third quarter was guided to “in the range of $2.3 million to $2.5 million” — Eric Hines, Chief Executive Officer · 2026-08-14; it delivered $2.2 million.

Recurring revenue is the thesis — and explicitly not yet the revenue

The keyword set for this quarter is a near-perfect map of the new story: disposable revenue is the single highest-momentum term in the deck, flanked by a genuinely new entry in intrathecal pump refills and the perennial epidural procedure tally of 30 million globally and 11 million in the U.S. The illustrative math — 2% U.S. penetration at $150 per procedure against roughly $33 million of annual disposables — is the kind of slide that sells a microcap. But Anthony Vendetti asked the only question that matters and got an answer that guts the near-term version of it. Of the roughly $100,000 of medical revenue in the quarter, “I would say right now it's skewed toward new sales, probably 85%” — Eric Hines, CEO · 2026-11-13 — and the recurrence is not imminent, because of a four-to-six-month lag from contract to training to Medicare submission to reimbursement: “I do not think that the recurring will really start to be a significant portion of the revenue probably until mid-Q1 of next year and Q2.” — Eric Hines, CEO · 2026-11-13 So the Q4 profitability claim rests on the same machinery that produced $2.2 million in Q3 — new unit placements and dental sales — not on the recurring engine that justifies the multiple. The unit economics the CEO cites are suggestive rather than reassuring: 25 to 50 CompuFlo purchasers by year-end, each "worth" $90,000–$100,000 annually at 50 cases a month, or roughly $450,000 a year from Rothman Orthopaedics alone at its 3,000 interlaminar Medicare procedures. Those are capacity figures, not conversion figures, and the same call concedes that adoption is uneven: “some embrace it very quickly and use it very successfully. Others have a little bit of a learning curve” — Eric Hines, CEO · 2026-11-13 — with field-training capacity as the binding constraint.

Everything that stopped being mentioned

The silences are more informative than the additions. Three things that carried weight on prior calls are simply gone. The dental ambassador program. Ambassador program was a headline initiative in the first half of 2026, with roughly 175–200 ambassadors recruited and a stated goal of “somewhere in the neighborhood of a few hundred thousand dollars of new sales as a result of the Ambassador program” — Eric Hines, Chief Executive Officer · 2026-04-01. This quarter it isn't named once. In its place: "online product demonstrations more than doubled" and discussions with four major dental distribution channels. The dental business still anchors the P&L, but the growth vehicle changed without anyone saying so. Japan, and the international registration timeline. India and Mexico have now slipped at least twice — promised for the prior quarter in April, then for September, now for Q1 2027 alongside a newly added Vietnam. And Japan, once "probably more in the September time frame," is parked: “Japan, I think we're holding off for just a little bit... we're holding off on Japan until further notice.” — Eric Hines, CEO · 2026-11-13 Guidance excludes all of them anyway, which makes the double-digit growth claim entirely a U.S. and existing-market story. The federal channel. Red One Medical, the VA/DoD distributor, was supposed to be taking orders. On the August call: “our goal is to be taking orders in Q4.” — Eric Hines, Chief Executive Officer · 2026-08-14 We are now in Q4. Red One appears only as a name in the commercial-infrastructure list, with no order update and no mention of the FSS schedule that was the original gating item. Also unmentioned: "Milo," the AI lead-qualification bot introduced last quarter as the fix for unreturned leads.

The tape already ran this movie once

The market gave the turnaround thesis a full round trip. The stock is down 21.5% over the last 90 days despite an initial six-week surge of 32% into an August 13 peak of $0.55 — then a 40% slide. At a $26 million market cap, the equity is priced at 2.6x revenue, down about 69% year over year. The balance sheet is debt-free after converting director loans to equity, but thin: $1.3 million of cash and $3.5 million of working capital against $2.4 million of quarterly operating expense. Liabilities-to-assets has climbed to 71.3% from roughly 40% a year ago — the loan conversion changed the label, not the capital need. One last tell: for the third consecutive call, Bruce Jackson asked whether the gross margin bump is sustainable, and for the third time got the same answer — expect a reversion to the high-60s/70% band as equipment mix shifts. The 72.3% print is a mix artifact, not a new margin regime. The story here is not complicated, it is just unusually falsifiable. Milestone has promised a profitable fourth quarter, on a revenue line that must jump 40% sequentially, driven by a segment where 85% of the money is still one-time hardware and the recurring half doesn't arrive until spring. The next call settles the first claim; the one after that settles the second.